About Adolor (NASDAQ:ADLR)
Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin). In December 2011, Cubist Pharmaceuticals, Inc. acquired Adolor Corporation.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Adolor (NASDAQ:ADLR) Frequently Asked Questions
What is Adolor's stock symbol?
Adolor trades on the NASDAQ under the ticker symbol "ADLR."
Who are some of Adolor's key competitors?
Some companies that are related to Adolor include Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Amazon.com (AMZN), Microsoft (MSFT), Facebook (FB), Intel (INTC), Cisco Systems (CSCO), Comcast (CMCSA), PepsiCo (PEP), Netflix (NFLX), Nvidia (NVDA), Amgen (AMGN), Adobe Systems (ADBE), Booking (BKNG), Texas Instruments (TXN), Broadcom (AVGO) and Gilead Sciences (GILD).
Has Adolor been receiving favorable news coverage?
Headlines about ADLR stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adolor earned a daily sentiment score of 0.22 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Adolor?
Shares of ADLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Adolor?
Adolor's mailing address is 700 Pennsylvania Dr, EXTON, PA 19341-1129, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581.
MarketBeat Community Rating for Adolor (ADLR)MarketBeat's community ratings are surveys of what our community members think about Adolor and other stocks. Vote "Outperform" if you believe ADLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Adolor (NASDAQ:ADLR) Analyst Ratings History
(Data available from 4/22/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Adolor (NASDAQ:ADLR) Earnings History and Estimates Chart
Adolor (NASDAQ ADLR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Adolor (NASDAQ:ADLR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Adolor (NASDAQ ADLR) Insider Trading and Institutional Ownership History
Adolor (NASDAQ ADLR) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Adolor (NASDAQ ADLR) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Adolor (NASDAQ:ADLR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Adolor (NASDAQ:ADLR) Income Statement, Balance Sheet and Cash Flow Statement
Adolor (NASDAQ ADLR) Stock Chart for Sunday, April, 22, 2018